Real‐World Practice and Challenges of Donor Lymphocyte Apheresis and Infusion: A Single‐Center Experience
Therapeutic Apheresis and Dialysis · 2025
DOI: 10.1111/1744-9987.70053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, 2025. Verfasst von Shuhei Kurosawa und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Lymphocyte Transfusion, Blood Component Removal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background
Although donor lymphocyte infusion (DLI) is a treatment option after posttransplant immunomodulation, data on donor lymphocyte apheresis (DLA) remain scarce.
Methods
We retrospectively analyzed 26 recipients receiving DLI and their related donors (human leukocyte antigen [HLA]‐matched, n = 9; haploidentical, n = 17).
Results
The median harvested CD3‐positive cell count (CD3) was 6.71 × 10 7 cells/kg (range, 3.55–19.74). A positive correlation was observed between harvested CD3 and preharvest lymphocyte counts (correlation coefficients = 0.78). In HLA‐matched DLI, the median infused CD3 was 1.19 × 10 7 per cycle and 4.56 × 10 7 cells/kg in total; in haploidentical DLI, 0.25 × 10 7 and 0.44 × 10 7 , respectively. The proportion of total infused CD3 relative to harvested CD3 was 26.3% (range, 2.7–100) in HLA‐matched DLI and 4.5% (range, 1.4–26.0) in HLA‐haploidentical DLI. [Correction added on 21 June 2025, after first online publication: The minimum and maximum value of range for infused CD3 proportion in HLA‐matched DLI and HLA‐haploindentical DLI has been corrected in this version.]
Conclusions
Our findings reflect real‐world practices and underscore the importance of tailoring DLA to donor and recipient characteristics, particularly in light of the increasing use of haploidentical donors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
- Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
ORCID-Profile: Shuhei Kurosawa
Zitieren
APA
Kurosawa, S., Haraguchi, K., Najima, Y., Uchibori, Y., Ishiwada, M., Honma, Y., Kawai, F., Watanabe, R., Iimura, R., Ishibashi, S., Sakuma, K., Narishima, K., Nishimura, M., Ouchi, F., Shimabukuro, M., Jinguji, A., Toya, T., Shimizu, H., Doki, N., & Okuyama, Y. (2025). Real‐World Practice and Challenges of Donor Lymphocyte Apheresis and Infusion: A Single‐Center Experience. Therapeutic Apheresis and Dialysis. https://doi.org/10.1111/1744-9987.70053
Vancouver
Kurosawa S, Haraguchi K, Najima Y, Uchibori Y, Ishiwada M, Honma Y, et al. Real‐World Practice and Challenges of Donor Lymphocyte Apheresis and Infusion: A Single‐Center Experience. Therapeutic Apheresis and Dialysis. 2025. doi:10.1111/1744-9987.70053
BibTeX
@article{Kurosawa2025,
author = {Kurosawa, Shuhei and Haraguchi, Kyoko and Najima, Yuho and Uchibori, Yusuke and Ishiwada, Moemi and Honma, Yunoka and Kawai, Fuyuko and Watanabe, Rei and Iimura, Ryoko and Ishibashi, Sayuri and Sakuma, Kae and Narishima, Kiyomi and Nishimura, Misako and Ouchi, Fumihiko and Shimabukuro, Masashi and Jinguji, Atsushi and Toya, Takashi and Shimizu, Hiroaki and Doki, Noriko and Okuyama, Yoshiki},
title = {Real‐World Practice and Challenges of Donor Lymphocyte Apheresis and Infusion: A Single‐Center Experience},
journal = {Therapeutic Apheresis and Dialysis},
year = {2025},
doi = {10.1111/1744-9987.70053}
}
EUVIMED